Easy Bruising and Proximal Weakness With Steroid Exposure

An adult develops easy bruising, facial rounding, new hypertension, proximal leg weakness, and worsening glucose after months of intermittent steroid injections plus a potent topical product obtained abroad. The phenotype suggests glucocorticoid excess, but the first diagnostic obligation is to identify every exogenous source because standard endogenous Cushing tests can mislead and abrupt withdrawal can precipitate adrenal crisis.

Case focus#

The decision is whether findings are explained by exogenous glucocorticoid exposure and hypothalamic-pituitary-adrenal suppression or whether a carefully selected screen for endogenous hypercortisolism is warranted after confounders are addressed. The plan must reduce excess safely while preventing adrenal insufficiency.

This analysis concentrates on calibration. It compares plausible explanations, asks which observations genuinely discriminate among them, and keeps the working diagnosis open to revision as new evidence arrives.

Problem representation#

The useful representation is not a label alone. It combines the tempo of the problem, the setting, the physiologic or functional threat, the evidence already available, and the important information that is still missing. For this glucocorticoid excess analysis, the working frame must remain broad enough to compare Exogenous Cushing syndrome with adrenal suppression, Pituitary ACTH-dependent Cushing disease, Adrenal cortisol-producing lesion, Ectopic ACTH syndrome without allowing a familiar first impression to become an untested conclusion.

The setting materially changes the plan: An endocrine clinic able to reconcile prescribed, injected, inhaled, topical, and nonprescription steroids and arrange validated hormonal testing.. Available monitoring, access to consultation, travel time, record continuity, and the reliability of follow-through alter what counts as a safe next step. A plan that is reasonable in a continuously monitored environment may be unsafe when results return after discharge or urgent reassessment is difficult.

Immediate safety priorities#

• Adrenal crisis features: Hypotension, vomiting, severe weakness, hypoglycemia, confusion, or collapse during dose reduction requires emergency glucocorticoid management.
• Serious infection: Fever, focal symptoms, or sepsis may be muted by steroids and requires a lower threshold for evaluation.
• Thromboembolism or cardiovascular decompensation: New chest pain, dyspnea, unilateral swelling, severe hypertension, or heart failure can complicate glucocorticoid excess.
• Severe psychiatric change: Mania, psychosis, suicidality, or profound depression can be steroid related and demands urgent safety assessment.

These findings are action signals rather than diagnostic shortcuts. They determine the pace of stabilization, consultation, and escalation while the causal analysis continues in parallel.

Prioritized differential diagnosis#

Exogenous Cushing syndrome with adrenal suppression#

What supports it. Multiple steroid routes, temporal progression, and suppressed endogenous cortisol support exposure-related disease.

What argues against it or keeps uncertainty open. Persistent hypercortisolism after verified clearance from exogenous steroids would require reconsideration.

Discriminating next step. Verify ingredients and timing, then assess adrenal recovery using guideline-consistent testing.

Pituitary ACTH-dependent Cushing disease#

What supports it. Progressive discriminatory features and confirmed endogenous hypercortisolism with ACTH dependence support a pituitary source.

What argues against it or keeps uncertainty open. Known exogenous exposure and suppressed ACTH/cortisol argue against it during active use.

Discriminating next step. Establish endogenous hypercortisolism with validated screening before pituitary imaging.

Adrenal cortisol-producing lesion#

What supports it. Confirmed ACTH-independent hypercortisolism supports an adrenal source.

What argues against it or keeps uncertainty open. Exogenous exposure and nonvalidated isolated cortisol values do not.

Discriminating next step. Measure ACTH only after biochemical confirmation, then image according to the established pathway.

Ectopic ACTH syndrome#

What supports it. Rapid severe hypercortisolism, hypokalemia, infection, and weight loss may support ectopic secretion.

What argues against it or keeps uncertainty open. A gradual exposure-linked phenotype without biochemical endogenous excess lowers probability.

Discriminating next step. Escalate endocrine evaluation after valid confirmation; do not start with indiscriminate body imaging.

Pseudo-Cushing physiology or phenocopy#

What supports it. Alcohol use disorder, major depression, uncontrolled diabetes, sleep disruption, or obesity can produce overlapping features and abnormal screens.

What argues against it or keeps uncertainty open. Wide purple striae, objective proximal weakness, spontaneous bruising, and osteoporosis are more discriminatory.

Discriminating next step. Address confounders and select repeat or second-line testing with endocrinology when results are equivocal.

The differential is ranked but not closed. Probability, consequence of delay, reversibility, and test burden are considered together. A dangerous alternative can deserve early exclusion even when it is not the statistically most likely explanation.

Evidence-gathering strategy#

• Exhaustive glucocorticoid inventory. Record oral, injected, inhaled, intranasal, topical, ocular, rectal, compounded, supplement, and drug-interaction exposures with dates. Interpretation: A credible exogenous source can explain both Cushing features and suppressed endogenous cortisol, changing the entire test sequence.
• Document discriminatory features and complications. Assess skin fragility, wide striae, objective proximal strength, blood pressure, glucose, infection, bone and eye risk, and mental state. Interpretation: Objective complications guide urgency and provide a baseline for recovery.
• Morning serum cortisol in the correct context. A timed value can help assess hypothalamic-pituitary-adrenal recovery after tapering to an interpretable dose. Interpretation: Very low values support continued adrenal-risk precautions; intermediate values often require planned retesting or dynamic assessment.
• Validated endogenous Cushing screening when truly indicated. Late-night salivary cortisol, 24-hour urinary free cortisol, or low-dose dexamethasone testing must be selected around shift work, kidney function, medicines, estrogen, and assay effects. Interpretation: Concordant abnormal tests support endogenous excess; discordant results require confounder review rather than immediate imaging.
• Medication interaction and product verification. CYP3A inhibitors and undeclared potent steroids can magnify exposure. Interpretation: Identifying an interaction or hidden ingredient enables safer deprescribing and prevents recurrence.

Tests are selected because they can change a decision, not because a broad panel feels comprehensive. Results are interpreted with their timing, pretest probability, measurement limitations, recent treatment, and the possibility that an apparently reassuring value was obtained too early or under the wrong conditions.

Progressive course and interpretation#

A complete product inventory uncovers repeated long-acting injections and daily high-potency topical use that were absent from the electronic medication list. Morning cortisol is interpreted in relation to dose timing and assay limitations. The care team coordinates a taper and replacement strategy where indicated, monitors recovery, and reserves endogenous testing for persistent features inconsistent with exposure.

The trajectory is evidence. Improvement after an intervention may support a mechanism without proving it, while nonresponse should prompt a check of the diagnosis, delivery of the intervention, timing, adherence, and competing pathology. Discordant data should be explained rather than averaged away.

Management reasoning#

• Do not stop chronic glucocorticoids abruptly. Tapering and physiologic replacement decisions depend on dose, duration, route, disease control, symptoms, and adrenal testing.
• Coordinate all prescribers. One accountable plan should reconcile injections, topical therapies, inhalers, and systemic medicines to prevent duplicated exposure.
• Provide adrenal-risk education when suppression is possible. Written sick-day, procedure, vomiting, and emergency instructions reduce crisis risk during recovery.
• Treat complications and provide steroid-sparing alternatives. Address blood pressure, glucose, bone health, infection, mood, and the underlying condition that prompted steroid use.
• Reassess recovery over time. Physical features and adrenal function recover at different rates; scheduled review avoids both premature discontinuation and indefinite unnecessary replacement.

Management remains proportional to severity and uncertainty. It includes explicit monitoring targets, foreseeable adverse effects, and stop or escalation conditions. Exact drug selection, dosing, and procedure details depend on verified individual factors, current local protocols, contraindications, and the responsible treating team; the analytical value here is the decision structure and its guardrails.

Communication and shared decisions#

Explain that steroids delivered by injection, inhaler, cream, eye drops, or unregulated products can enter the bloodstream and suppress the body's cortisol system. Avoid blaming the person for using prescribed or accessible treatments; clarify why stopping suddenly may be dangerous and provide written stress-dose and emergency instructions when applicable.

The communication task includes what is known, what remains uncertain, why the next step is recommended, what alternatives exist, and which change should trigger urgent reassessment. Teach-back, qualified interpretation when needed, accessible formats, and a named owner for pending results turn information into a safer plan.

Continuity and safety net#

• Seek emergency help for collapse, severe vomiting, hypotension, confusion, or inability to take required glucocorticoid during illness.
• Contact the prescribing team before procedures, major illness, or dose changes so stress coverage and taper instructions are clear.
• Report fever, new focal infection symptoms, severe mood change, chest pain, or unilateral leg swelling promptly.
• Carry the current steroid plan and adrenal-risk information across pharmacies, urgent care, dental care, and hospital encounters.

Follow-through is verified, not assumed. The record should identify who receives each pending result, the time window for reassessment, the contingency if contact fails, and the clinical or functional outcome that will show whether the plan is working.

Equity and systems analysis#

Fragmented prescribing, cash clinics, imported products, low health literacy, and lack of dermatology or pain alternatives increase cumulative exposure. Ask to see containers and photos without judgment, reconcile across pharmacies and experts, and ensure the taper is affordable with an accessible emergency plan.

Access conditions belong in the causal model. Transportation, medication cost, work schedules, caregiving, health literacy, language, disability access, digital connectivity, and prior experiences of care can alter both the observed presentation and the feasibility of the plan. Addressing those constraints improves diagnostic validity as well as fairness.

Reasoning capabilities demonstrated#

• Links bruising, proximal weakness, facial change, hypertension, and dysglycemia to glucocorticoid excess while first inventorying injections, creams, inhalers, drops, supplements, and imported products.
• Distinguishes exogenous exposure with hypothalamic-pituitary-adrenal suppression from endogenous Cushing syndrome before ordering tests that steroid timing can render misleading.
• Interprets morning cortisol and any subsequent endocrine studies against formulation, dose, timing, assay limitations, and persistent features unexplained by the exposure history.
• Coordinates a safe taper or replacement plan, stress dosing when indicated, comorbidity monitoring, recovery testing, and affordable alternatives to the original steroid treatment.
• Explains systemic absorption and adrenal-crisis risk without blaming fragmented prescribing, and provides written emergency instructions that remain usable across pharmacies and clinicians.

Key takeaways#

• The most important first test may be a complete exposure history, not a cortisol assay.
• Exogenous glucocorticoids can cause both Cushing features and dangerous adrenal suppression.
• Imaging before valid biochemical confirmation invites incidental findings and diagnostic error.